🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are on the rise worldwide, with estimates suggesting more than 82 million infections each year. Notably increased rates are reported in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

According to results released by a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This establishes an equal footing with the existing first-line therapy, which involves two antibiotics. The trial involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed optimism. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as vital to reduce the burden of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.